| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$7.1M | ROE | −194.20% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $5.0M | Trading Days | 1237 |
| 52W High | 7.33 |
| 52W Low | 1.10 |
| % Off High | −83.15% |
| YTD | −46.77% | 1Y | −82.43% |
| 3Y | −99.39% | Since incept. (ann.) | −84.50% |
| Ann. Volatility (1Y) | 121.97% | Ann. Volatility (3Y) | 129.32% |
| Sharpe (1Y) | −0.88 | Sharpe (3Y) | −0.77 |
| Max Drawdown (1Y) | −83.85% | Max Drawdown (3Y) | −99.46% |
| Beta (3Y, vs SPY) | 0.90 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ENVB | Enveric Biosciences, Inc. | $4.9M | — |
| RNAZ | Transcode Therapeutics, Inc. | $4.8M | — |
| APVO | Aptevo Therapeutics Inc. | $5.2M | — |
| INBP | INTEGRATED BIOPHARMA INC | $4.7M | 5.0 |
| GOVX | GeoVax Labs, Inc. | $5.4M | — |
| SNGX | SOLIGENIX, INC. | $5.4M | — |
| LIANY | LianBio | $5.4M | — |
| RVPH | REVIVA PHARMACEUTICALS HOLDINGS, INC. | $5.5M | — |
| INM | InMed Pharmaceuticals Inc. | $5.5M | — |
| CURX | Curanex Pharmaceuticals Inc | $5.6M | — |
| XBIO | Xenetic Biosciences, Inc. | $5.7M |
| — |
| ELAB | PMGC Holdings Inc. | $4.3M | — |
